The global bone morphogenetic proteins market will experience significant growth through 2022, according to a Transparency Market Research report.
Here are five observations:
1. North America dominates the market at present, capturing a market share of more than 70 percent.
2. An awareness of BMP products and an increase in spinal fusion procedures will spur the North American market.
3. Europe follows North America in terms of market share, and the Asia Pacific region will experience the highest market growth through 2022.
4. The rhBMP-2 market segment captured the largest market share in 2013, with its increasing popularity for use in spinal fusions.
5. The spinal fusions segment dominates the market in terms of application, with trauma following.
6. Dublin, Ireland-based Medtronic; Lyon, France-based Olympus Biotech; and South Korea-based Cellumed lead the space.